Bitcoin pioneer Charlie Shrem peels back the layers on the lives and backgrounds of the world's most impactful innovators. Centering around intimate narratives, Shrem uncovers a detailed, previously unspoken story of the genesis and evolution of bitcoin, cryptocurrency, artificial intelligence, and the web3 movements. Join Shrem as he journeys through the uncharted territories of tech revolutions, revealing the human side of the stories that shaped the digital world we live in today.
…
continue reading
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
IXICO CEO on strong 2025 performance, 2026 priorities
MP3•منزل الحلقة
Manage episode 513979265 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strong performance in 2025, highlighting above-guidance revenue delivery and continued progress in its strategic focus areas. Goorden detailed how the 'Innovate, Lead, Scale' strategy has driven growth, with three core pillars: new contract wins, contract extensions, and expansion into new verticals such as blood-based biomarkers. Discussing full-year trading, Goorden noted a boost in new contracts, particularly within neurology and Alzheimer’s disease, aligning with IXICO’s strategic goals. He emphasised that “we start to now also see that, especially for Alzheimer's disease in revenue.” Contract extensions also played a significant role, including one in a major Alzheimer’s program. Additionally, IXICO’s movement into validating diagnostic blood tests was underlined by a new deal in this space, further building on earlier work with companies like Fujirebio. Goorden addressed the effective use of capital raised in the prior year, confirming investments in innovation, personnel, and US operational scale-up were all “on track” and have now moved into the execution phase. Looking ahead to 2026, the company aims to maintain its trajectory and highlight innovations more publicly, potentially exploring new partnerships. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications. #IXICO #Biomarkers #Neurology #AlzheimersResearch #BloodBiomarkers #BiotechNews #ClinicalTrials #DiagnosticValidation #HealthcareTech #InvestorUpdates
…
continue reading
606 حلقات
MP3•منزل الحلقة
Manage episode 513979265 series 2891889
المحتوى المقدم من Proactive Investors. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة Proactive Investors أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) CEO Bram Goorden talked with Proactive's Stephen Gunnion about the company’s strong performance in 2025, highlighting above-guidance revenue delivery and continued progress in its strategic focus areas. Goorden detailed how the 'Innovate, Lead, Scale' strategy has driven growth, with three core pillars: new contract wins, contract extensions, and expansion into new verticals such as blood-based biomarkers. Discussing full-year trading, Goorden noted a boost in new contracts, particularly within neurology and Alzheimer’s disease, aligning with IXICO’s strategic goals. He emphasised that “we start to now also see that, especially for Alzheimer's disease in revenue.” Contract extensions also played a significant role, including one in a major Alzheimer’s program. Additionally, IXICO’s movement into validating diagnostic blood tests was underlined by a new deal in this space, further building on earlier work with companies like Fujirebio. Goorden addressed the effective use of capital raised in the prior year, confirming investments in innovation, personnel, and US operational scale-up were all “on track” and have now moved into the execution phase. Looking ahead to 2026, the company aims to maintain its trajectory and highlight innovations more publicly, potentially exploring new partnerships. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications. #IXICO #Biomarkers #Neurology #AlzheimersResearch #BloodBiomarkers #BiotechNews #ClinicalTrials #DiagnosticValidation #HealthcareTech #InvestorUpdates
…
continue reading
606 حلقات
ทุกตอน
×مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.